S.2535 - Opioid Quota Reform Act115th Congress (2017-2018)
|Sponsor:||Sen. Durbin, Richard J. [D-IL] (Introduced 03/12/2018)|
|Committees:||Senate - Judiciary|
|Latest Action:||Senate - 06/19/2018 Placed on Senate Legislative Calendar under General Orders. Calendar No. 473. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.2535 — 115th Congress (2017-2018)All Information (Except Text)
Introduced in Senate (03/12/2018)
Opioid Quota Reform Act
This bill amends the Controlled Substances Act to require the Drug Enforcement Administration (DEA) to consider additional factors—the impact on overall public health and rates of diversion, abuse, and overdose deaths—in setting and adjusting production and manufacturing quotas for fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone.
Additionally, if the DEA increases the production quota of fentanyl, oxycodone, hydrocodone, oxymorphone, or hydromorphone, then it must explain why the public health benefits of increasing the quota outweigh the consequences of potential diversion.